Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) updated its FY17 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.05. The company issued revenue guidance of $220-230 million, compared to the consensus revenue estimate of $233.60 million.
A number of research analysts have recently commented on the company. Jefferies Group LLC dropped their price target on Sucampo Pharmaceuticals from $13.00 to $11.00 and set a hold rating for the company in a research note on Thursday, May 4th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a strong sell rating to a hold rating in a research note on Tuesday, July 4th. Maxim Group reiterated a buy rating and issued a $21.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, April 13th. Mizuho reiterated a buy rating and issued a $14.00 price target on shares of Sucampo Pharmaceuticals in a research note on Tuesday, April 4th. Finally, ValuEngine cut Sucampo Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $17.00.
Sucampo Pharmaceuticals, Inc. (SCMP) traded up 0.93% during mid-day trading on Wednesday, reaching $10.80. The company had a trading volume of 79,593 shares. The firm has a 50-day moving average price of $10.58 and a 200 day moving average price of $10.73. The firm has a market capitalization of $501.81 million, a price-to-earnings ratio of 18.00 and a beta of 1.48. Sucampo Pharmaceuticals, Inc. has a 12-month low of $9.30 and a 12-month high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a net margin of 11.36% and a return on equity of 43.27%. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.24 earnings per share. Analysts expect that Sucampo Pharmaceuticals, Inc. will post $1.04 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Updates FY17 Earnings Guidance” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/02/sucampo-pharmaceuticals-inc-nasdaqscmp-updates-fy17-earnings-guidance.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
